Emily Calasanz, MD
Obstetrics & Gynecology · Dallas, TXNPI 1487073557
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 35.1% of the total. Reporting peaked in 2020 at $689 and has fallen 97.6% since, to $16 in 2025.
Across 66 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$556
- Lupin Inc.$266
- Tris Pharma Inc$125
- Acessa Health Inc.$85
- Avion Pharmaceuticals$82
- Coopersurgical, Inc.$74
- plus $394 from 15 others
What the payments were for
- Food & beverage$1,583100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $556 |
| Lupin Inc. | 10 | $266 |
| Tris Pharma Inc | 1 | $125 |
| Acessa Health Inc. | 1 | $85 |
| Avion Pharmaceuticals | 6 | $82 |
| Coopersurgical, Inc. | 4 | $74 |
| Hologic Sales And Service, LLC | 3 | $60 |
| Exeltis, USA Inc. | 3 | $55 |
| Aspira Women's Health Inc | 2 | $42 |
| Merck | 2 | $33 |
| Mylan Pharmaceuticals Inc. | 2 | $33 |
| Pfizer | 2 | $25 |
| Bayer | 1 | $19 |
| Duchesnay USA Incorporated | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Roche Diagnostics Corporation | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $15 |
| Ascend Therapeutics US, LLC | 1 | $13 |
| Minerva Surgical, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$127
- Dyanavel XR$125
- SOLOSEC$121
How this compares
$1,583 in reported general payments places this provider in the 60th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 11 | $373 |
| Norethindrone | 14 | $225 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Dallas
- Dale StovallDallas$590K
- Quanita CrableDallas$176K
- Kamilia SmithDallas$119K
- Yolanda LawsonDallas$96K
- Patrick WeixDallas$96K
- David RogersDallas$44K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.